Siddha herbo-mineral drug Kandhaga Rasayanam in the treatment of Dermatophytoses (Padarthamarai)

Meena Rajarethinam; Ramaswamy Selvaratnam Ramaswamy

doi:10.53730/ijhs.v6nS10.13601

Authors

Meena Rajarethinam
meenaprakashphd@gmail.com
Research Officer (Siddha), Siddha Central Research Institute, (Central Council for Research in Siddha, Ministry of AYUSH, Government of India), Anna arch, Arumbakkam, Chennai, 600106, Tamil Nadu, India
Ramaswamy Selvaratnam Ramaswamy Former Director General, Central Council for Research in Siddha, Ministry of AYUSH, Govt. of India, Govt. Anna Hospital Campus, Arumbakkam, Chennai 600106, Tamil Nadu, India

Keywords:

dermatophytosis, Kandhaga Rasayanam, clinical trials, clinical parameters, hematological parameters

Abstract

The symptoms of dermatophytosis goes congruent with the disease entity Padarthamarai in Siddha medicine. Kandhaga Rasayanam (KR) is a Siddha herbo-mineral formulation indicated for padarthamarai. In recent times, treatment of dermatophytosis challenge to dermatologists. The present study was carried out to clinically evaluate the efficacy of KR as a trial drug for Dermatophytosis. The objective of the present study was to study the efficacy of the drug KR in giving mycological and clinical cure. This was an open-label, non-randomized, single -arm clinical study in which 51 patients of either gender diagnosed with padarthamarai were included. The trial was registered in Clinical trials registry India with CTRI number CTRI/2012/01/002362. The treatment period was 45 days. Out of the 51 participants enrolled in this study, 45 participants were included in the final analysis based on their adherence to the conditions. 66.67% showed skin scraping negative for dermatophytes. There was a significant reduction in the clinical signs after the treatment without any adverse reactions. This trial has brought to limelight the efficacy of the Siddha drug Kandhaga Rasayanam in treating padarthamarai . Further, randomized controlled clinical trials are necessary to substantiate the traditional claim and make KR a plausible treatment option for Dermatophytosis.

Downloads

Download data is not yet available.

References

Aditya KG, Jennifer ER, Melody C, Elizabeth AC (2005) Dermatophytosis: The Management of Fungal Infections. Skinmed 4(5): 305-310 doi:10.1111/j.1540-9740.2005. 03435.x

Botter AA, Dethier F, Mertens RL, et al (1979) Skin and nail mycoses: treatment with ketoconazole, a new oral antimycotic agent. Mykosen 22:274–278.

Das S, De A, Saha R, Sharma N, Khemka M, Singh S, Hesanoor Reja AH, Kumar P (2020) The Current Indian Epidemic of Dermatophytosis: A Study on Causative Agents and Sensitivity Patterns. Indian J Dermatol 65(2):118-122. doi: 10.4103/ijd.IJD_203_19. PMID: 32180597; PMCID: PMC7059464.

Elman S, Hynan LS, Gabriel V, Mayo MJ (2010) The 5-D itch scale: a new measure of pruritus. Br J Dermatol 162(3):587-593. doi:10.1111/j.1365-2133.2009. 09586.x

Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210-216.

Hainer BL (2003) Dermatophyte infections. Am Fam Physician. 67(1):101-8. PMID: 12537173.

Krzywinski M., Altman N (2013) Significance, P values and t-tests. Nat Methods 10:1041–1042. https://doi.org/10.1038/nmeth.2698

Kuppuswamy Mudhaliyaar, editor (2016) Siddha Maruthuvam (Podhu) Chenna 687.

Kurade S, Amladi S, Miskeen A (2006) Skin scraping and a potassium hydroxide mount. Indian J. Dermatol. Venereol. Leprol 72:238–241.

Meena R, Punithavathy PM, Ramaswamy RS (2018) MIC of A Siddha Formulation Kandhaga Rasayanam against Dermatophytes, Int J Pharm Sci Rev Res 50(2):37-40.

Meena R, Ramaswamy RS (2015) Therapeutic potency of a Siddha formulation Kandhaga Rasayanam: A review. Int J Res Ayurveda Pharm 6(1):58-64.

Meena R, Ramaswamy RS (2018) Long term toxicity study of a Siddha formulation Kandhaga rasayanam (KR) in Rats. Res J Pharm Technol 11(4):1640-1646.

Meena R, Ramaswamy RS (2019) Treating pundareega kuttam (dermatophytosis) with a siddha herbo mineral formulation: a single case study Int.J. Res.Ayurveda Pharm. 10(3): 103 -106.

Meena.R, Ramaswamy. RS, Shakila. R (2014) Physico chemical analysis of Kandhaga Rasayanam, a Siddha herbomineral formulation IOSR Journal of Pharmacy 4 (2): 28-34

Mushtaq S, Faizi N, Amin SS, Adil M, Mohtashim M (2020) Impact on quality of life in patients with dermatophytosis. Australas J Dermatol 61(2): e184-e188. doi: 10.1111/ajd.13191.

Naglot A, Shrimali DD, Nath BK, Gogoi HK, Vijay V, Chander J and Tewari R (2015) Recent trends of Dermatophytosis in Northeast India (Assam) and interpretation with published studies. Int J Curr Microbiol App Sci 4(11):111–120.

Narang T, Bhattacharjee R, Singh S, Jha K, Kavita, Mahajan R, Dogra S (2019) Quality of life and psychological morbidity in patients with superficial cutaneous dermatophytosis. Mycoses 62(8):680-685. doi: 10.1111/myc.12930.

Pihet M, Le Govic Y (2017) Reappraisal of Conventional Diagnosis for Dermatophytes. Mycopathologia 182:169–180.

Porter G, Grills N (2016) Medication misuse in India: A major public health issue in India. J Public Health 38(2):150–157.

Ranganathan S, Menon T, Selvi SG et al. (1995) Effect of socioeconomic status on the prevalence of dermatophytosis in Madras. Indian J Dermatol Venereol Leprol 61(1):16–17.

Singh S, Shukla P (2018) End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol 84(5):554-557.

Surendran KAK, Bhat RM, Boloor R, Nandakishore B, et al. A Clinical and Mycological Study of Dermatophytic Infections, Indian J Dermatol. 2014;59(3):262–267. Doi: 10.4103/0019-5154.131391

Verma S, Madhu R (2017) The great Indian epidemic of superficial dermatophytosis: An appraisal, Indian J Dermatol. 62(3):227–236. Doi: 10.4103/ijd.IJD_206_17

Williams DI, Marten RH, Sarkany I (1958) Oral treatment of ringworm with griseofulvin. Lancet.2:1212–1213.